Skip to main content
Equibles
COLL logo

COLL · Collegium Pharmaceutical, Inc · Webcasts, Transcripts & Audio

Track COLL — free

Use COLL with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research COLL.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$21.87 -0.15 (-0.68%)
S&P 600 member Russell 2000 member Rebalance outlook locked
Market Cap
$721.76M
Shares
32.56M
Volume · Oct 5 975.4K Avg daily vol (3M) 735.38K

Collegium Pharmaceutical, Inc Webcasts

Earnings calls, investor updates, investor days and conferences for Collegium Pharmaceutical, Inc (COLL), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP →

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲61.1% $127.01M $457,000 '22 Q3 22-11-03 ▲373.7% $129.62M −$7.20M '22 Q4 23-02-23 ▲72.9% $144.77M −$17.43M '23 Q1 23-05-04 ▲9.7% $135.55M $13.01M '23 Q2 23-08-03 ▲7.6% $136.71M $20.63M '23 Q3 23-11-07 ▲15.5% $149.75M $31.94M '23 Q4 24-02-22 ▲0.1% $144.92M $27.71M '24 Q1 24-05-09 ▲7.2% $145.28M $19.61M '24 Q2 24-08-08 ▲16.5% $159.30M $9.34M '24 Q3 24-11-07 ▲21.5% $181.95M $12.54M '24 Q4 25-02-27 ▲22.7% $177.76M $2.42M '25 Q1 25-05-08 ▲29.4% $188.00M $11.98M '25 Q2 25-08-07 ▲31.4% $209.36M $31.51M '25 Q3 25-11-06 ▲12.9% $205.45M $16.96M '25 Q4 26-02-26 ▲8.9% $193.52M $14.50M '26 Q1 26-05-07 LATEST ▲6.3% $199.88M −$15.05M '26 Q2 26-08-06
Conference
Investor event
2026-09-16
Collegium Pharmaceutical, Inc (COLL) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-09-15
Collegium Pharmaceutical, Inc (COLL) September 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Collegium Pharmaceutical, Inc (COLL) Q2 2026 Earnings Call Transcript
Confident tone Astaris acquisition and integration ADHD growth (Jornay PM) Pain portfolio performance
Revenue
$199.88M
▲ 6.3% YoY
Diluted EPS
$-0.46
▼ 235.3% YoY
Gross margin
55.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-03
Collegium Pharmaceutical, Inc (COLL) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Collegium Pharmaceutical, Inc (COLL) Q1 2026 Earnings Call Transcript
Confident tone AZSTARYS Acquisition Pain Portfolio Durability ADHD Sales Force & Market Coverage
Revenue
$193.52M
▲ 8.9% YoY
Diluted EPS
$0.40
▲ 471.4% YoY
Gross margin
60.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-04-15
Collegium Pharmaceutical, Inc (COLL) April 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-03-19
Collegium Pharmaceutical, Inc (COLL) March 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY25 · Q4
2026-02-26
Collegium Pharmaceutical, Inc (COLL) Q4 2025 Earnings Call Transcript
Confident tone Pain portfolio durability Jornay PM growth Capital deployment / business development
Revenue
$205.45M
▲ 12.9% YoY
Diluted EPS
$0.46
▲ 27.8% YoY
Gross margin
62.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-06
Collegium Pharmaceutical, Inc (COLL) Q3 2025 Earnings Call Transcript
Confident tone Jornay PM Growth Pain Portfolio Performance Gross-to-Net & Inventory Dynamics
Revenue
$209.36M
▲ 31.4% YoY
Diluted EPS
$0.84
▲ 211.1% YoY
Gross margin
61.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Collegium Pharmaceutical, Inc (COLL) Q2 2025 Earnings Call Transcript
Confident tone Jornay PM Growth Jornay Awareness / Marketing Pain Portfolio Durability / Generic Defense
Revenue
$188.00M
▲ 29.4% YoY
Diluted EPS
$0.34
▼ 34.6% YoY
Gross margin
57.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Collegium Pharmaceutical, Inc (COLL) Q1 2025 Earnings Call Transcript
Confident tone Jornay PM Growth Pain Portfolio Durability Sales Force Expansion
Revenue
$177.76M
▲ 22.7% YoY
Diluted EPS
$0.07
▼ 90.1% YoY
Gross margin
54.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-27
Collegium Pharmaceutical, Inc (COLL) Q4 2024 Earnings Call Transcript
Confident tone Jornay PM growth and ADHD franchise Pain portfolio (BELBUCA, Xtampza ER, Nucynta) Sales force expansion for Jornay
Revenue
$181.95M
▲ 21.5% YoY
Diluted EPS
$0.36
▼ 56.1% YoY
Gross margin
54.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Collegium Pharmaceutical, Inc (COLL) Q3 2024 Earnings Call Transcript
Confident tone ADHD market growth opportunity Pain portfolio performance Business development pipeline
Revenue
$159.30M
▲ 16.5% YoY
Diluted EPS
$0.27
▼ 49.1% YoY
Gross margin
60.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Collegium Pharmaceutical, Inc (COLL) Q2 2024 Earnings Call Transcript
Confident tone Ironshore Acquisition / Jornay PM Pain Portfolio Performance Financial Results
Revenue
$145.28M
▲ 7.2% YoY
Diluted EPS
$0.52
▲ 52.9% YoY
Gross margin
62.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Collegium Pharmaceutical, Inc (COLL) Q1 2024 Earnings Call Transcript
Confident tone Xtampza ER Performance Belbuca Growth Nucynta Franchise Outlook
Revenue
$144.92M
▲ 0.1% YoY
Diluted EPS
$0.71
Gross margin
63.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-22
Collegium Pharmaceutical, Inc (COLL) Q4 2023 Earnings Call Transcript
Confident tone Xtampza ER contract renegotiations BELBUCA growth and outlook Nucynta exclusivity extension
Revenue
$149.75M
▲ 15.5% YoY
Diluted EPS
$0.82
Gross margin
63.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Collegium Pharmaceutical, Inc (COLL) Q3 2023 Earnings Call Transcript
Revenue
$136.71M
▲ 7.6% YoY
Diluted EPS
$0.53
▲ 5200% YoY
Gross margin
58.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Collegium Pharmaceutical, Inc (COLL) Q2 2023 Earnings Call Transcript
Revenue
$135.55M
▲ 9.7% YoY
Diluted EPS
$0.34
Gross margin
54.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-04
Collegium Pharmaceutical, Inc (COLL) Q1 2023 Earnings Call Transcript
Revenue
$144.77M
▲ 72.9% YoY
Diluted EPS
$-0.51
Gross margin
53.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-23
Collegium Pharmaceutical, Inc (COLL) Q4 2022 Earnings Call Transcript
Revenue
$129.62M
▲ 373.7% YoY
Diluted EPS
$-0.21
Gross margin
38.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Collegium Pharmaceutical, Inc (COLL) Q3 2022 Earnings Call Transcript
Revenue
$127.01M
▲ 61.1% YoY
Diluted EPS
$0.01
▼ 95.5% YoY
Gross margin
46.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Collegium Pharmaceutical, Inc (COLL) Q2 2022 Earnings Call Transcript
Revenue
$123.55M
▲ 49% YoY
Diluted EPS
$-0.15
▼ 108.4% YoY
Gross margin
42.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-10
Collegium Pharmaceutical, Inc (COLL) Q1 2022 Earnings Call Transcript
Revenue
$83.75M
▼ 4.5% YoY
Diluted EPS
$-0.39
▼ 195.1% YoY
Gross margin
57.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-24
Collegium Pharmaceutical, Inc (COLL) Q4 2021 Earnings Call Transcript
Revenue
$27.36M
▼ 64.1% YoY
Diluted EPS
$-0.73
▼ 465% YoY
Gross margin
-4.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-04
Collegium Pharmaceutical, Inc (COLL) Q3 2021 Earnings Call Transcript
Revenue
$78.84M
▼ 0.4% YoY
Diluted EPS
$0.22
▼ 31.2% YoY
Gross margin
58.5%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-05
Collegium Pharmaceutical, Inc (COLL) Q2 2021 Earnings Call Transcript
Revenue
$82.94M
▲ 6.3% YoY
Diluted EPS
$1.79
▲ 678.3% YoY
Gross margin
60.6%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Collegium Pharmaceutical, Inc (COLL) Q1 2021 Earnings Call Transcript
Revenue
$87.72M
▲ 14.7% YoY
Diluted EPS
$0.41
▲ 4000% YoY
Gross margin
63.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-02-25
Collegium Pharmaceutical, Inc (COLL) Q4 2020 Earnings Call Transcript
Revenue
$76.27M
▲ 2.8% YoY
Diluted EPS
$0.20
Gross margin
58.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Collegium Pharmaceutical, Inc (COLL) Q3 2020 Earnings Call Transcript
Revenue
$79.18M
▲ 8.5% YoY
Diluted EPS
$0.32
Gross margin
60.9%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-05
Collegium Pharmaceutical, Inc (COLL) Q2 2020 Earnings Call Transcript
Revenue
$78.06M
▲ 4% YoY
Diluted EPS
$0.23
Gross margin
62.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Collegium Pharmaceutical, Inc (COLL) Q1 2020 Earnings Call Transcript
Revenue
$76.51M
▲ 2.7% YoY
Diluted EPS
$0.01
Gross margin
51.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-02-27
Collegium Pharmaceutical, Inc (COLL) Q4 2019 Earnings Call
Revenue
$74.20M
▲ 1.1% YoY
Gross margin
33.8%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–32 of 32 webcasts
Key facts CIK 1267565 CUSIP 19459J104 13F (30d) 5 filings 5 filers Visit website Investor relations